Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a diversified line of healthcare products including: drugs, nutritional products, diabetes monitoring devices and diagnostics.
All pharmaceutical companies face the inevitable patent expirations and the ensuing generic competition. However, ABT’s product pipeline includes potential significant launches in the medical device and pharmaceutical areas. With its strong financials and excellent management team, ABT is in a position to continue its growth and to generate strong returns. I will continue to add to my position while it is trading below my buy price of $61.24 and as my allocation allows.
Source: Dividends Value
Related Articles:
Dividend Growth Stocks News
- 2 Dividend Stocks Yielding 7% to Pounce on Now - Yahoo Finance - 8/7/2025
- How to Build RRSP Wealth Using Dividend Stocks - ca.finance.yahoo.com - 8/8/2025
- How I’d Invest $250,000 in Canadian Dividend Stocks - MSN - 8/8/2025
- 3 Ultra-High-Yield Dividend Stocks -- Sporting an Average Yield of 6.72% -- That Make for No-Brainer Buys in August - The Globe and Mail - 8/5/2025
- 3 Asian Dividend Stocks To Consider With At Least 3.6% Yield - Yahoo Finance - 8/7/2025
- Raytheon Technologies Corporation (RTX) Dividend Stock Analysis - 7/31/2025
- Duke Energy (DUK) Dividend Stock Analysis - 7/25/2025
- Chevron Corporation (CVX) Dividend Stock Analysis - 7/18/2025
- Emerson Electric Co. (EMR) Dividend Stock Analysis - 7/11/2025
- Amgen, Inc. (AMGN) Dividend Stock Analysis - 6/27/2025
Stock Analysis: Abbott Laboratories (ABT)
Posted by D4L | Thursday, May 06, 2010 | ArticleLinks | 0 comments »________________________________________________________________
Subscribe to:
Post Comments (Atom)
0 comments
Post a Comment
Post a Comment
Note: Only a member of this blog may post a comment.